An Introduction To A Novel Antimalarial Drug ?aretrolane Maleate And Piperaquine Phospahte? | 13350
Clinical Pharmacology & Biopharmaceutics
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Estimated 300-500 million people contract malaria each year, resulting in 1.5-2.7 million deaths annually. According to published
research in ?Malaria Journal? (2011), the very low adherence to artemether-lumefantrine raises serious concerns for the malaria
control, as this can results in inadequate cure and development antimalarial resistance. The adjudicated published results show
205000 malaria deaths per year in India before age 70. Poor-quality antimalarial drugs lead to drug resistance and inadequate
treatment, which pose an urgent threat to vulnerable populations and jeopardise progress and investments in combating malaria.
Emergence of artemisinin resistance or tolerance in
on the Thailand-Cambodia border makes protection
of the effectiveness of the drug supply imperative. Arterolane Maleate and Pipraquine Phosphate is a fixed dose combination
developed for the treatment of acute, uncomplicated P. falciparum malaria in adults, approved in 2011 by Drug Controller General
of India. Arterolane Maleate and Pipraquine Phosphate is developed in line with WHO recommendations of using fixed dose
combination formulation of a rapid/short acting anti-malarial drug (arterolane) with long-acting anti-malarial partner drug
(piperaquine) with complementary effects. Arterolane Maleate and Pipraquine Phosphate provides high clinical efficacy as assessed
by ACPR, FCT and PCT. Arterolane Maleate and Pipraquine Phosphate has demonstrated faster median fever clearance time in
phase III clinical trial. Arterolane Maleate and Pipraquine Phosphate has achieved high cure rate in Malaria endemic countries
with widespread Chloroquine resistance. Arterolane Maleate and Pipraquine Phosphate achieved 28- day PCR corrected ACPR of
97.9% in uncomplicated falciparum Malaria.
Jeetu Gangil has completed his Master of pharmacy at the age of 27 years from Manipal University, Karnataka, India. Jeetu Gangil is working in
Innovative Product Team in Ranbaxy Laboratories Pvt ltd, a premier pharmaceutical and research organization. He has published various papers in
reputed journals and pharma magazines.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals